Artivion (NYSE:AORT) Price Target Raised to $50.00

Key Points

• Needham & Company LLC has increased its target price for Artivion (NYSE:AORT) from $45.00 to $50.00, indicating a potential upside of 15.97% from the stock's previous close.
• Artivion recently reported an earnings per share of $0.24 for the quarter, significantly beating the consensus estimate of $0.11, with a revenue of $112.97 million.
• Institutional ownership of Artivion stands at 86.37%, with notable recent investments from firms like Public Sector Pension Investment Board and Canada Life Assurance Co.

Artivion (NYSE:AORT - Get Free Report) had its price target raised by Needham & Company LLC from $45.00 to $50.00 in a report released on Friday,Benzinga reports. The firm currently has a "buy" rating on the stock. Needham & Company LLC's target price would indicate a potential upside of 13.69% from the stock's previous close.

Other analysts have also issued reports about the stock. Wall Street Zen lowered shares of Artivion from a "buy" rating to a "hold" rating in a research note on Sunday, August 17th. Citizens Jmp raised Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. Oppenheimer reaffirmed an "outperform" rating on shares of Artivion in a report on Friday, August 8th. Canaccord Genuity Group raised their price objective on shares of Artivion from $35.00 to $41.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Finally, LADENBURG THALM/SH SH cut Artivion from a "buy" rating to a "neutral" rating and upped their target price for the company from $32.00 to $38.80 in a research report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $40.63.

Artivion Trading Down 0.1%

Shares of Artivion stock traded down $0.05 on Friday, reaching $43.98. The company had a trading volume of 148,226 shares, compared to its average volume of 444,095. Artivion has a 52-week low of $21.97 and a 52-week high of $45.07. The firm's 50 day moving average price is $34.23 and its two-hundred day moving average price is $29.03. The firm has a market cap of $2.07 billion, a PE ratio of -104.70 and a beta of 1.64. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.48 and a current ratio of 4.78.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.13. The firm had revenue of $112.97 million for the quarter, compared to the consensus estimate of $107.96 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The business's quarterly revenue was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. Sell-side analysts predict that Artivion will post 0.37 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Artivion news, SVP Marshall S. Stanton sold 15,000 shares of the firm's stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $29.50, for a total transaction of $442,500.00. Following the completion of the sale, the senior vice president owned 64,200 shares in the company, valued at $1,893,900. This trade represents a 18.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John E. Davis sold 10,802 shares of the stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $43.67, for a total transaction of $471,723.34. Following the transaction, the insider directly owned 208,778 shares in the company, valued at $9,117,335.26. The trade was a 4.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 97,790 shares of company stock valued at $3,634,659 over the last ninety days. Insiders own 8.10% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. LPL Financial LLC lifted its holdings in Artivion by 10.9% in the 4th quarter. LPL Financial LLC now owns 19,623 shares of the company's stock valued at $561,000 after acquiring an additional 1,925 shares during the last quarter. Wells Fargo & Company MN boosted its position in Artivion by 22.1% during the 4th quarter. Wells Fargo & Company MN now owns 34,823 shares of the company's stock worth $996,000 after acquiring an additional 6,299 shares during the period. Invesco Ltd. increased its stake in Artivion by 22.7% in the 4th quarter. Invesco Ltd. now owns 267,067 shares of the company's stock valued at $7,635,000 after buying an additional 49,462 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Artivion during the fourth quarter worth $275,000. Finally, Barclays PLC increased its holdings in Artivion by 1.2% in the fourth quarter. Barclays PLC now owns 71,697 shares of the company's stock worth $2,051,000 after buying an additional 820 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company's stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.